Ectoline 50 mg Spot-On Solution for Cats and Kittens over 8 weeks above 1kg

Main information

  • Trade name:
  • Ectoline 50 mg Spot-On Solution for Cats and Kittens over 8 weeks above 1kg
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Ectoline 50 mg Spot-On Solution for Cats and Kittens over 8 weeks above 1kg
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • fipronil
  • Therapeutic area:
  • Cats

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0309/001
  • Authorization date:
  • 31-01-2012
  • EU code:
  • UK/V/0309/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:January2012

AN:01617/2011

Page1of8

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

ALFAMED50mgspot-onsolutionforcats

(DE:FIPROLINE,FR:TICK-PUSS,IT:PROCAREFICONTROL,UK:ECTOLINE

50mgspot-onsolutionforcatsandKittensover8weeksabove1kg

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

One0.5mlpipettecontains:

Activesubstance:

Fipronil 50mg

Excipients:

ButylhydroxyanisoleE320 0.1mg/pipette

ButylhydroxytolueneE321 0.05mg/pipette

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution.

Clear,colourlesstoyellowsolution.

4. CLINICALPARTICULARS

4.1Targetspecies

Cats.

4.2Indicationsforuse

Treatmentofflea(Ctenocephalidesspp.)andtick(Dermacentorreticulatus)

infestations.

Theproducthasapersistentinsecticidalefficacyforupto5weeksagainstfleas

(Ctenocephalidesfelis).

Theproducthasapersistentacaricidalefficacyforupto2weeksagainstticks

(Rhipicephalussanguineus,Ixodesricinus,Dermacentorreticulatus).Ifticksof

somespecies(RhipicephalussanguineusandIxodesricinus)arepresentwhen

theproductisapplied,alltheticksmaynotbekilledwithinthefirst48hoursbut

theymaybekilledwithinaweek.

TheproductcanbeusedaspartofatreatmentstrategyforthecontrolofFlea

AllergyDermatitis(FAD)wherethishasbeenpreviouslydiagnosedbyaveterinary

surgeon.

Revised:January2012

AN:01617/2011

Page2of8

Revised:January2012

AN:01617/2011

Page3of8

4.3Contraindications

Intheabsenceofavailabledata,theproductshouldnotbeusedonkittensless

than2monthsoldand/orweighinglessthan1kg.

Donotuseonsick(systemicdiseases,fever…)orconvalescentanimals.

Donotuseinrabbits,asadversedrugreactionsandevendeathcouldoccur.

Donotuseincasesofhypersensitivitytotheactivesubstanceortoanyof

excipients.

4.4Specialwarningsforeachtargetspecies

Fleasfrompetsofteninfesttheanimal'sbasket,beddingandregularrestingareas

suchascarpetsandsoftfurnishingswhichshouldbetreated,incaseofmassive

infestationandatthebeginningofthecontrolmeasures,withasuitableinsecticide

andvacuumedregularly.

Theproductdoesnotpreventticksfromattachingtotheanimals.Iftheanimalhas

beentreatedpriortoexposuretotheticks,thetickswillbekilledinthefirst24-48

hoursafterattachment.Thiswillusuallybepriortoengorgement,minimisingbut

notexcludingtheriskoftransmissionofdiseases.Oncedead,tickswilloftendrop

offtheanimal,butanyremainingticksmayberemovedwithagentlepull.

Nodataontheeffectofbathing/shampooingontheefficacyoftheproductincats

areavailable.However,basedoninformationavailablefordogs,shampooingan

hourpriortotreatmentdoesnotaffecttheefficacyoftheproductagainstfleas.

WhenusedaspartofastrategyforthetreatmentofFleaAllergyDermatitis,

monthlyapplicationstotheallergicpatientandtoothercatsinthehouseholdare

recommended.

Foroptimumcontroloffleaproblemsinamulti-pethousehold,alldogsandcatsin

thehouseholdshouldbetreatedwithasuitableinsecticide.

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Avoidcontactwiththeanimal’seyes.Inthecaseofaccidentaleyecontact,

immediatelyandthoroughlyflushtheeyeswithwater.

Donotapplytheproductonwoundsordamagedskin.

ii.Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Thisproductcancausemucousmembraneandeyeirritation.Therefore,

contactbetweentheproductandthemouthoreyesshouldbeavoided.

Revised:January2012

AN:01617/2011

Page4of8

Inthecaseofaccidentaleyecontact,immediatelyandthoroughlyflushthe

eyeswithwater.Ifeyeirritationpersistsseekmedicaladviceandshowthe

packageleafletorthelabeltothephysician.

Avoidcontentscomingintocontactwiththefingers.Ifthisoccurs,wash

handswithsoapandwater.Washhandsafteruse.

Donotsmoke,drinkoreatduringapplication.

Animalsoroperatorswithaknownhypersensitivitytofipronilorexcipients

(seesection6.1.)shouldavoidcontactwiththeveterinarymedicinalproduct.

Treatedanimalsshouldnotbehandleduntiltheapplicationsiteisdry,and

childrenshouldnotbeallowedtoplaywithtreatedanimalsuntilthe

applicationsiteisdry.Itisthereforerecommendedthatanimalsarenot

treatedduringtheday,butshouldbetreatedduringtheearlyevening,and

thatrecentlytreatedanimalsshouldnotbeallowedtosleepwithowners,

especiallychildren.

iii.Otherprecautions

Thealcoholcarriermayhaveadverseeffectsonpainted,varnishedorother

householdsurfacesorfurnishings.

4.6Adversereactions(frequencyandseriousness)

Iflickingoccurs,abriefperiodofhypersalivationmaybeobservedduemainlyto

thenatureofthecarrier.

Amongtheextremelyraresuspectedadversereactions,transientcutaneous

reactionsattheapplicationsite(squamosis,localalopecia,pruritus,erythema)

andgeneralpruritusoralopeciahavebeenreportedafteruse.Exceptionally,

hypersalivation,reversibleneurologicsymptoms(hyperesthesia,depression,

nervoussymptoms)orvomitinghavebeenobservedafteruse.

4.7Useduringpregnancyandlactation

Laboratorystudiesusingfipronilhavenotshownanyevidenceofteratogenicor

embryotoxiceffects.Studieshavenotbeencarriedoutwiththisproductin

pregnantandlactatingqueens.Useinpregnancyandlactationonlyinaccordance

withprofessionalveterinaryadviceandabenefit/riskassessment.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

Revised:January2012

AN:01617/2011

Page5of8

4.9Amountstobeadministeredandadministrationroute

Routeofadministrationanddosage:

Externaluseonly.

Administerbytopicalapplicationtotheskin1pipetteof0.5mlperanimal.

Methodofadministration:

Thermoformedpipettes:

Holdthepipetteupright.Tapthenarrowpartofthepipettetoensurethatthe

contentsarewithinthemainbodyofthepipette.Breakthesnap-offtopofthespot-

onpipettealongthescoredline.

Partthepet’scoatuntilitsskinisvisible.Placethetipofthepipettedirectly

againstthebaredskinandsqueezegentlyseveraltimestoemptyitscontents

Repeatthisprocedureatoneortwodifferentpointsalongthecat’sback,

preferablyatthebaseoftheheadandbetweentheshoulders.

Polypropylenepipettes:

Removethepipettefromtheblisterpackaging.Holdthepipetteinanupright

position,twistandpullthecapoff.Turnthecaparoundandplacetheotherendof

thecapbackonthepipette.Twistthecaptobreaktheseal,thenremovethecap

fromthepipette.

Partthepet’scoatuntilitsskinisvisible.Placethetipofthepipettedirectly

againstthebaredskinandsqueezegentlyseveraltimestoemptyitscontents.

Repeatthisprocedureatoneortwopointsalongt hecat’sback,preferablyatthe

baseoftheheadandbetweentheshoulders.

Itisimportanttomakesurethattheproductisappliedtoanareawheretheanimal

cannotlickitoff,andtomakesurethatanimalsdonotlickeachotherfollowing

treatment.

Careshouldbetakentoavoidexcessivewettingofthehairwiththeproductsince

thiswillcauseastickyappearanceofhairsatthetreatmentspot.However,should

thisoccur,itwilldisappearwithin24hourspostapplication.

Revised:January2012

AN:01617/2011

Page6of8

Whitedepositsmayalsobeseenatthesiteforupto48hoursafterapplication.

Treatmentschedule:

Foroptimalcontroloffleaand/ortickinfestationthetreatmentschedulecanbe

basedonthelocalepidemiologicalsituation.

Intheabsenceofsafetystudies,theminimumtreatmentintervalis4weeks.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noadverseeffectswereobservedintargetanimalsafetystudiesincatsand

kittensaged2monthsandolderandweighingabout1kgtreatedatfivetimesthe

recommendeddose(dailytherapeuticdoseappliedonfiveconsecutivedays)for

threeconsecutivemonthsexceptforitchingandvomitingthatoccurredonce.The

riskofadverseeffectsmayincreaseincasesofover-dose.

4.11Withdrawalperiod

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Ectoparasiticidesfortopicaluse.

ATCvetcode:QP53AX15

5.1Pharmacodynamicproperties

Fipronilisaninsecticideandacaricidebelongingtothephenylpyrazolefamily.It

actsbyinhibitingtheGABAcomplex,bindingtothechloridechannelandthereby

blockingpre-andpost-synaptictransferofchlorideionsacrosscellmembranes.

Thisresultsinuncontrolledactivityofthecentralnervoussystemanddeathof

insectsoracarids.

Fipronilexhibitsaninsecticidalandacaricidalactivityagainstfleas

(Ctenocephalidesspp)andticks(Rhipicephalusspp,Dermacentorspp,Ixodes

spp.includingIxodesricinus)inthecat.

Fleaswillbekilledwithin24h.Tickswillusuallybekilledwithin48haftercontact

withFipronil,howeverifticksofsomespecies(Rhipicephalussanguineusand

Ixodesricinus)arepresentwhentheproductisapplied,alltheticksmaynotbe

killedwithinthefirst48hours.

5.2Pharmacokineticparticulars

Invitro,fipronilismainlymetabolisedwithsubcellularliverfractionstoitssulfone

derivative.However,thismaybeoflimitedrelevance‘invivo’asfipronilispoorly

absorbedinthecat.Theconcentrationsoffipronilonthehairdecreasewithtime.

Revised:January2012

AN:01617/2011

Page7of8

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxyanisoleE320

ButylhydroxytolueneE321

Benzylalcohol

Diethyleneglycolmonoethylether

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4.Specialprecautionsforstorage

Storebelow30

C.Storeinadryplace.Storeintheoriginalpackage.

6.5Natureandcompositionofimmediatepackaging

Thermoformedpipettes:Whiteortransparentmulti-layerplasticsingle-dose

pipettecontaininganextractiblevolumeof0.5ml.

Theinternallayersincontactwiththeproductaremadeofpolyacrylonitrile-

methacrylate.Thewhiteexternalcomplexiscomposedofpolypropylene/cyclic

olefinecopolymer/polypropylene.

Boxesof1,2,3,4,6,8,12,24,30,60,90or150pipettes.

Polypropylenepipettes:Whitepolypropylenesingle-dosepipettecontainingan

extractiblevolumeof0.5mlpackagedinuncolouredplasticblistercomposedof

polypropylene/cyclicolefinecopolymer/polypropyleneclosedbyheatsealing

withathermosealablelacqueredaluminiumfoilandplacedinacartonboxor

blistercard.

Blistercardsorboxesof1,2,3,4,6,8,12,24,30,60,90or150pipettes.

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

Fipronilmayadverselyaffectaquaticorganisms.Donotcontaminateponds,

waterwaysorditcheswiththeproductoremptycontainer.

Revised:January2012

AN:01617/2011

Page8of8

7. MARKETINGAUTHORISATIONHOLDER

Alfamed

13èmerue –L.I.D.

06517CarrosCedex

France

+33(0)492087304

+33(0)492087348

8. MARKETINGAUTHORISATIONNUMBER

Vm 17902/4015

9. DATEOFFIRSTAUTHORISATION

Date:16April2009

10.DATEOFREVISIONOFTHETEXT

Date:January2012

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

There are no news related to this product.